Literature DB >> 21482412

SUMO and its role in human diseases.

Kevin D Sarge1, Ok-Kyong Park-Sarge.   

Abstract

The covalent attachment of small ubiquition-like modifier (SUMO) polypeptides, or sumoylation, is an important regulator of the functional properties of many proteins. Among these are many proteins implicated in human diseases including cancer and Huntington's, Alzheimer's, and Parkinson's diseases, as well as spinocerebellar ataxia 1 and amyotrophic lateral sclerosis. The results of two more recent studies identify two additional human disease-associated proteins that are sumoylated, amyloid precursor protein (APP), and lamin A. APP sumoylation modulates Aβ peptide levels, suggesting a potential role in Alzheimer's disease, and decreased lamin A sumoylation due to mutations near its SUMO site has been implicated in causing some forms of familial dilated cardiomyopathy.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482412     DOI: 10.1016/B978-0-12-386041-5.00004-2

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  32 in total

Review 1.  Biology, pathology, and therapeutic targeting of RAS.

Authors:  J Matthew Rhett; Imran Khan; John P O'Bryan
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 2.  Targeting SUMO-1ylation Contrasts Synaptic Dysfunction in a Mouse Model of Alzheimer's Disease.

Authors:  Serena Marcelli; Elena Ficulle; Filomena Iannuzzi; Enikö Kövari; Robert Nisticò; Marco Feligioni
Journal:  Mol Neurobiol       Date:  2016-10-13       Impact factor: 5.590

3.  Construction of a mouse Aos1-Uba2 chimeric SUMO-E1 enzyme, mAU, and its expression in baculovirus-insect cells.

Authors:  Tomofumi Nakayama; Eri Yuasa; Ayumi Kanemaru; Masayuki Saito; Hisato Saitoh
Journal:  Bioengineered       Date:  2014-01-13       Impact factor: 3.269

Review 4.  SUMO proteomics to decipher the SUMO-modified proteome regulated by various diseases.

Authors:  Wei Yang; Wulf Paschen
Journal:  Proteomics       Date:  2014-10-28       Impact factor: 3.984

5.  Allosteric Inhibition of Ubiquitin-like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme.

Authors:  Yi-Jia Li; Li Du; Jianghai Wang; Ramir Vega; Terry D Lee; Yunan Miao; Grace Aldana-Masangkay; Eric R Samuels; Baozong Li; S Xiaohu Ouyang; Sharon A Colayco; Ekaterina V Bobkova; Daniela B Divlianska; Eduard Sergienko; Thomas D Y Chung; Marwan Fakih; Yuan Chen
Journal:  Cell Chem Biol       Date:  2018-12-20       Impact factor: 8.116

6.  SENP2 regulated the stability of β-catenin through WWOX in hepatocellular carcinoma cell.

Authors:  Qing-Feng Jiang; Yu-Wei Tian; Quan Shen; Huan-Zhou Xue; Ke Li
Journal:  Tumour Biol       Date:  2014-06-27

7.  Development of a high-throughput screening assay for inhibitors of small ubiquitin-like modifier proteases.

Authors:  Wei Yang; Liangli Wang; Wulf Paschen
Journal:  J Biomol Screen       Date:  2013-03-07

8.  Covalent small ubiquitin-like modifier (SUMO) modification of Maf1 protein controls RNA polymerase III-dependent transcription repression.

Authors:  Aarti D Rohira; Chun-Yuan Chen; Justin R Allen; Deborah L Johnson
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

9.  In vivo localization and identification of SUMOylated proteins in the brain of His6-HA-SUMO1 knock-in mice.

Authors:  Marilyn Tirard; He-Hsuan Hsiao; Miroslav Nikolov; Henning Urlaub; Frauke Melchior; Nils Brose
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-03       Impact factor: 11.205

Review 10.  Battling Alzheimer's Disease: Targeting SUMOylation-Mediated Pathways.

Authors:  Wagner Carbolin Martins; Carla Inês Tasca; Helena Cimarosti
Journal:  Neurochem Res       Date:  2015-07-31       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.